English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Buck, D., Andlauer, T. F. M., Igl, W., Wicklein, E.-M., Muehlau, M., Weber, F., et al. (2019). Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. MULTIPLE SCLEROSIS JOURNAL, 25(4), 565-573. doi:10.1177/1352458518763089.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Buck, Dorothea, Author
Andlauer, Till F. M.1, Author           
Igl, Wilmar, Author
Wicklein, Eva-Maria, Author
Muehlau, Mark, Author
Weber, Frank2, Author           
Koechert, Karl, Author
Pohl, Christoph, Author
Arnason, Barry, Author
Comi, Giancarlo, Author
Cook, Stuart, Author
Filippi, Massimo, Author
Hartung, Hans-Peter, Author
Jeffery, Douglas, Author
Kappos, Ludwig, Author
Barkhof, Frederik, Author
Edan, Gilles, Author
Freedman, Mark S., Author
Montalban, Xavier, Author
Mueller-Myhsok, Bertram3, Author           
Hemmer, Bernhard, Author more..
Affiliations:
1Dept. Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society, ou_2035295              
2Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              
3RG Statistical Genetics, Max Planck Institute of Psychiatry, Max Planck Society, ou_2040288              

Content

show
hide
Free keywords: -
 Abstract: Background: Treatment of multiple sclerosis (MS) with interferon beta can lead to the development of antibodies directed against interferon beta that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon beta. Objective: To validate the proposed genetic markers and to identify new markers. Methods: Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon beta-1b in the BetaferonA (R) Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseronA (R)/BEtaferonA (R) in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials. All patients were treated with interferon beta-1b for at least 6 months. In addition, a genome-wide association study was conducted to identify new genetic variants. Results: We confirmed an increased risk for carriers of HLA-DRB1*04:01 (odds ratio (OR) = 3.3, p = 6.9 x 10(-4)) and HLA-DRB1*07:01 (OR = 1.8, p = 3.5 x 10(-3)) for developing neutralizing antibodies (NAbs). Several additional, previously proposed HLA alleles and genetic variants showed nominally significant associations. In the exploratory analysis, variants in the HLA region were associated with NAb development at genome-wide significance (OR = 2.6, p = 2.30 x 10(-15)). Conclusion: The contribution of HLA alleles and HLA-associated single-nucleotide polymorphisms (SNPs) to the development and titer of antibodies against interferon beta was confirmed in the combined analysis of two multi-national, multi-center studies.

Details

show
hide
Language(s):
 Dates: 2019
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000461643500010
DOI: 10.1177/1352458518763089
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: MULTIPLE SCLEROSIS JOURNAL
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 25 (4) Sequence Number: - Start / End Page: 565 - 573 Identifier: ISSN: 1352-4585